Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Hicks

Anatomic Pathology Rochester, NY Medical Doctor

NPI 1386617157 CMS profile 16949

601 Elmwood Avenue, University Of Rochester Medical Center, Box 626, Rochester, NY 14642

Open in the dashboard

General payments

$169,365

139 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Hicks of Rochester, NY is reported in the CMS Open Payments database as having received $169,365 across 139 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Anatomic Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,711 16
2024 General $8,770 8
2023 General $17,674 20
2022 General $35,363 20
2021 General $21,988 11
2020 General $28,400 19
2019 General $44,458 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Hicks
  • Anatomic Pathology median
  • Middle half of Anatomic Pathology
  • National median

In program year 2025, general payments to David Hicks were reported at $12,711. Among 419 Anatomic Pathology profiles paid that year, the median was $110 and the middle half received between $28 and $974.

Show as a table
Year David Hicks Anatomic Pathology median Middle half National median
2019 $44,458 $112 $31–$404 $163
2020 $28,400 $185 $25–$4,265 $114
2021 $21,988 $121 $24–$2,629 $132
2022 $35,363 $121 $31–$1,816 $149
2023 $17,674 $96 $28–$1,008 $160
2024 $8,770 $103 $28–$1,069 $164
2025 $12,711 $110 $28–$974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $77,656 54 payments
  2. Genentech USA, Inc. $31,141 22 payments
  3. E.R. Squibb & Sons, L.L.C. $25,627 26 payments
  4. Ventana Medical Systems, Inc. $11,300 5 payments
  5. Merck Sharp & Dohme Corporation $5,310 8 payments
  6. AstraZeneca UK Limited $5,143 2 payments
  7. Daiichi Sankyo Inc. $4,529 9 payments
  8. Siemens Medical Solutions USA, Inc. $3,919 1 payment
  9. Agilent Technologies, Inc. $3,000 1 payment
  10. F. Hoffmann-La Roche AG $700 1 payment
  11. Other $1,040 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $96,686 52 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $53,074 17 payments
  3. Travel and Lodging $13,890 34 payments
  4. Education $3,979 4 payments
  5. Food and Beverage $1,735 32 payments
Products named General payments · program years 2019–2025
  1. ENHERTU Oncology $36,025 29 payments
  2. BENCHMARK IHC/ISH PLATFORMS & REAGENTS $6,200 2 payments
  3. OPDIVO $5,084 10 payments
  4. INFORM HER2 Dual ISH DNA Probe Cocktail $4,800 2 payments
  5. ENHERTU Oncology $4,529 9 payments
  6. SPRYCEL $3,966 1 payment
  7. ADVIA Centaur XP Analyzer $3,919 1 payment
  8. LYNPARZA $3,025 1 payment
  9. PD-L1 IHC 28-8 PHARMDX $3,000 1 payment
  10. Lucentis $1,695 1 payment
  11. Other $7,049 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$22,348

Medicare's payments for the services billed

Medicare patients

235

Average age 71

Services billed

726

167 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Cancer 57%
Arthritis 49%
Diabetes 31%
Depression 30%
Chronic kidney disease 26%
Ischemic heart disease 25%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

139 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anatomic Pathology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record